BenevolentAI Scoops $115M For AI Drug Development
Executive Summary
At a pre-money valuation of $2bn, BenevolentAI raises $115m to develop artificial intelligence approach that already can cut early drug development timeline by four years.
You may also be interested in...
AZ Inks Machine Learning Deal With BenevolentAI
The company's biopharma R&D chief tells Scrip about trying to unlock the potential of the the vast amount of data produced to improve the understanding of complex disease biology and identify new targets to treat debilitating diseases.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.